MARIA RITA DE FIGUEIREDO LEMOS BORTOLOTTO

(Fonte: Lattes)
Índice h a partir de 2011
5
Lattes
ORCID
Projetos de Pesquisa
Unidades Organizacionais
Instituto Central, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/57 - Laboratório de Fisiologia Obstétrica, Hospital das Clínicas, Faculdade de Medicina

Filtros

Limpar filtros

Configurações

Tipo de produção: article ×

Resultados de Busca

Agora exibindo 1 - 10 de 11
  • article 10 Citação(ões) na Scopus
    Use of a Minimally Invasive Uncalibrated Cardiac Output Monitor in Patients Undergoing Cesarean Section under Spinal Anesthesia: Report of Four Cases
    (2011) BLIACHERIENE, Fernando; CARMONA, Maria Jose Carvalho; BARRETTI, Cristina de Freitas Madeira; HADDAD, Cristiane Maria Federicci; MOUCHALWAT, Elaine Soubhi; BORTOLOTTO, Maria Rita de Figueiredo Lemos; FRANCISCO, Rossana Pulcineli Vieira; ZUGAIB, Marcelo
    Bliacheriene F, Carmona MJC, Barretti CFM, Haddad CMF, Mouchalwat ES, Bortlotto MRFL, Francisco RPV, Zugaib M - Use of a Minimally Invasive Uncalibrated Cardiac Output Monitor in Patients Undergoing Cesarean Section under Spinal Anesthesia: Report of Four Cases. Background and Objectives: Hemodynamic changes are observed during cesarean section under spinal anesthesia. Non-invasive blood pressure (BP) and heart rate (HR) measurements are performed to diagnose these changes, but they are delayed and inaccurate. Other monitors such as filling pressure and cardiac output (CO) catheters with external calibration are very invasive or inaccurate. The objective of the present study was to report the cardiac output measurements obtained with a minimally invasive uncalibrated monitor (LiDCO rapid) in patients undergoing cesarean section under spinal anesthesia. Case report: After approval by the Ethics Commission, four patients agreed to participate in this study. They underwent cesarean section under spinal anesthesia while at the same time being connected to the LiDCO rapid by a radial artery line. Cardiac output, HR, and BP were recorded at baseline, after spinal anesthesia, after fetal and placental extraction, and after the infusion of oxytocin and metaraminol. We observed a fall in BP with an increase of HR and CO after spinal anesthesia and oxytocin infusion; and an increase in BP with a fall in HR and CO after bolus of the vasopressor. Conclusions: Although this monitor had not been calibrated, it showed a tendency for consistent hemodynamic data in obstetric patients and it may be used as a therapeutic guide or experimental tool.
  • article 11 Citação(ões) na Scopus
    Pregnancy in Women with Complex Congenital Heart Disease. A Constant Challenge
    (2019) AVILA, Walkiria Samuel; RIBEIRO, Veronica Martins; ROSSI, Eduardo Giusti; BINOTTO, Maria Angelica; BORTOLOTTO, Maria Rita; TESTA, Carolina; FRANCISCO, Rossana; HAJJAR, Ludhmilla Abraao; MIURA, Nana
    Background: The improvement in surgical techniques has contributed to an increasing number of childbearing women with complex congenital heart disease (CCC). However, adequate counseling about pregnancy in this situation is uncertain, due to a wide variety of residual cardiac lesions. Objectives: To evaluate fetal and maternal outcomes in pregnant women with CCC and to analyze the predictive variables of prognosis. Methods: During 10 years we followed 435 consecutive pregnancies in patients (pts) with congenital heart disease. Among of them, we selected 42 pregnancies in 40 (mean age of 25.5 +/- 4.5 years) pts with CCC, who had been advised against pregnancy. The distribution of underlying cardiac lesions were: D-Transposition of the great arteries, pulmonary atresia, tricuspid atresia, single ventricle, double-outlet ventricle and truncus arteriosus. The surgical procedures performed before gestation were: Fontan, Jatene, Rastelli, Senning, Mustard and other surgical techniques, including Blalock, Taussing, and Glenn. Eight (20,0%) pts did not have previous surgery. Nineteen 19 (47.5%) pts had hypoxemia. The clinical follow-up protocol included oxygen saturation recording, hemoglobin and hematocrit values; medication adjustment to pregnancy, anticoagulation use, when necessary, and hospitalization from 28 weeks, in severe cases. The statistical significance level considered was p < 0.05. Results: Only seventeen (40.5%) pregnancies had maternal and fetal uneventful courses. There were 13 (30.9%) maternal complications, two (4.7%) maternal deaths due to hemorrhage pos-partum and severe pre-eclampsia, both of them in women with hypoxemia. There were 7 (16.6%) stillbirths and 17 (40.5%) premature babies. Congenital heart disease was identified in two (4.1%) infants. Maternal and fetal complications were higher (p < 0.05) in women with hypoxemia. Conclusions: Pregnancy in women with CCC was associated to high maternal and offspring risks. Hypoxemia was a predictive variable of poor maternal and fetal outcomes. Women with CCC should be advised against pregnancy, even when treated in specialized care centers.
  • article 8 Citação(ões) na Scopus
    Can thrombophilia worsen maternal and perinatal outcomes in cases of severe preeclampsia?
    (2018) BAPTISTA, Fernanda Spadotto; BORTOLOTTO, Maria Rita de Figueiredo Lemos; BIANCHINI, Fabiola Roberta Marim; KREBS, Vera Lucia Jornada; ZUGAIB, Marcelo; FRANCISCO, Rossana Pulcinelli Vieira
    Objective: To evaluate whether thrombophilia worsens maternal and foetal outcomes among patients with severe preeclampsia (PE). Method: From October 2009 to October 2014, an observational retrospective cohort study was performed on pregnant women with severe PE diagnosed before 34 weeks of gestation and their newborns hospitalized at the Clinics Hospital, FMUSP. Patients who had no heart disease, nephropathies, pre-gestational diabetes, gestational trophoblastic disease, foetal malformation, or twin pregnancy and who underwent thrombophilia screening during the postnatal period were included. New pregnancies of the same patient; cases of foetal morphological, genetic, or chromosomal abnormalities after birth; and women who used heparin or acetylsalicylic acid during pregnancy were excluded. Factor V Leiden, G20210A prothrombin mutation, antithrombin, protein C, protein S, homocysteine, lupus anticoagulant, and anticardiolipin IgG and IgM antibodies were analysed. The groups with and without thrombophilia were compared regarding their maternal clinical and laboratory parameters and perinatal outcomes. Results: Of the 127 patients selected, 30 (23.6%) had thrombophilia (hereditary or acquired). We found more white patients in thrombophilia group (p = .036). Analysis of maternal parameters showed a tendency of thrombophilic women to have more thrombocytopenia (p = .056) and showed worsening of composite laboratory abnormalities (aspartate aminotransferase >= 70 mg/dL, alanine aminotransferase >= 70 mg/dL, platelets < 100,000/mm(3), serum creatinine >= 1.1 mg/dL; p = .017). There were no differences in foetal perinatal outcomes. Conclusion: The presence of thrombophilia leads to worsening of maternal laboratory parameters among patients with severe forms of PE but without worsening perinatal outcomes.
  • article 2 Citação(ões) na Scopus
    Agranulocytosis and puerperal sepsis in woman after the use of ceftriaxone
    (2011) CANDIDO, Haliana Muzio; BORTOLOTTO, Maria Rita; STRABELLI, Tania Mara Varejao; BENVENUTI, Luiz Alberto
  • article 11 Citação(ões) na Scopus
    I DIRETRIZ DE INSUFICIÊNCIA CARDÍACA (IC) E TRANSPLANTE CARDÍACO, NO FETO, NA CRIANÇA E EM ADULTOS COM CARDIOPATIA CONGÊNITA, DA SOCIEDADE BRASILEIRA DE CARDIOLOGIA
    (2014) AZEKA, E.; JATENE, M. B.; JATENE, I. B.; HOROWITZ, E. S. K.; BRANCO, K. C.; SOUZA NETO, J. D.; MIURA, N.; MATTOS, S.; AFIUNE, J. Y.; TANAKA, A. C.; SANTOS, C. C. L.; GUIMARAES, I. C. B.; MANSO, P. H.; PELLIZARI, R. C. R. S.; SANTOS, M. V. C.; THOMAZ, A. M.; CRISTOFANI, L. M.; RIBEIRO, A. C. L.; KULIKOWSKI, L. D.; SAMPAIO, M. C.; PEREIRA, A. C.; SOARES, A. M.; SOARES JUNIOR, J.; OH, G. H. Y.; MOREIRA, V; MOTA, C. C. C.; AFIUNE, C. M. C.; PEDRA, C.; PEDRA, S.; PEDROSA, A.; GUIMARAES, V; CANEO, L. F.; FERREIRO, C. R.; CAVALHEIRO FILHO, C.; STEFANELLO, B.; NEGRAO, C. E.; TURQUETTO, A. L. R.; MESQUITA, S. M. F.; MAEDA, W. T.; ZORZANELLI, L.; PANAJOTOPOLOS, N.; SIQUEIRA, A. W. S.; GALAS, F. R. B.; HAJJAR, L. A.; BENVENUTI, L. A.; VINCENZI, P.; ODONE, V; LOPES, M. H.; V, T. M. Strabelli; FRANCHI, S. M.; TAKEUTI, A. D.; DUARTE, M. F.; LEON, R. G. P.; HERMIDA, R. P. M.; SORPRESO, I. C. E.; SOARES JUNIOR, J. M.; MELO, N. R.; BARACAT, E. C.; BORTOLOTTO, M. R. F. L.; SCANAVACCA, M.; SHIMODA, M. S.; FORONDA, G.; ROMANO, B. W.; SILVA, D. B.; OMURA, M. M.; BARBEIRO, C. P. M.; VINHOLE, A. R. G.; PALOMO, J. S. H.; GONCALVES, M. A. B.; REIS, I. C. F.; OLIVEIRA, L. G.; RIBEIRO, C. C.; ISOSAKI, M.; VIEIRA, L. P.; FELTRIM, M. I. Z.; MANOEL, L. A.; ABUD, K. C. O.; PASCHOTTO, D. R.; NEVES, I. L. I.; SENAHA, L. E.; GARCIA, A. C. C. N.; CIPRIANO, S. L.; SANTOS, V. C.; FERRAZ, A. S.; MOREIRA, A. E. L. C.; PAULO, A. R. S. A. De; DUQUE, A. M. P. C.; TRINDADE, E.; BACAL, F.; AULER JUNIOR, J. O. C.; ALMEIDA, D. R.
  • article 0 Citação(ões) na Scopus
    Cardiovascular diseases worsen the maternal prognosis of COVID-19
    (2023) TESTA, Carolina Burgarelli; GODOI, Luciana Graziela de; BORTOLOTTO, Maria Rita de Figueiredo Lemos; MONROY, Nataly Adriana Jimenez; MATTOS, Bruna Rodrigues de; RODRIGUES, Agatha Sacramento; FRANCISCO, Rossana Pulcineli Vieira
    Cardiovascular diseases (CVD) are a risk factor for severe cases of COVID-19. There are no studies evaluating whether the presence of CVD in pregnant and postpartum women with COVID-19 is associated with a worse prognosis. In an anonymized open database of the Ministry of Health, we selected cases of pregnant and postpartum women who were hospitalized due to COVID-19 infection and with data regarding their CVD status. In the SIVEP GRIPE data dictionary, CVD is defined as ""presence of cardiovascular disease"", excluding those of neurological and nephrological causes that are pointed out in another field. The patients were divided into two groups according to the presence or absence of CVD (CVD and non-CVD groups). Among the 1,876,953 reported cases, 3,562 confirmed cases of pregnant and postpartum women were included, of which 602 had CVD. Patients with CVD had an older age (p<0,001), a higher incidence of diabetes (p<0,001) and obesity (p<0,001), a higher frequency of systemic (p<0,001) and respiratory symptoms (p<0,001). CVD was a risk factor for ICU admission (p<0,001), ventilatory support (p = 0.004) and orotracheal intubation in the third trimester (OR 1.30 CI95%1.04-1.62). The group CVD had a higher mortality (18.9% vs. 13.5%, p<0,001), with a 32% higher risk of death (OR 1.32 CI95%1.16-1.50). Moreover, the risk was increased in the second (OR 1.94 CI95%1.43-2.63) and third (OR 1.29 CI95%1.04-1.60) trimesters, as well as puerperium (OR 1.27 CI95%1.03-1.56). Hospitalized obstetric patients with CVD and COVID-19 are more symptomatic. Their management demand more ICU admission and ventilatory support and the mortality is higher.
  • article 4 Citação(ões) na Scopus
    Anesthesia for cardiac surgery under cardiopulmonary bypass in pregnant patients: experience with nine cases
    (2012) BLIACHERIENE, F.; AVILA, W. S.; BORTOLOTTO, M. R. F. L.; OKANO, F. T.; FONTES, E. S.; GALAS, F. R. B. G.; CARMONA, M. J. C.
  • article
    7TH BRAZILIAN GUIDELINE OF ARTERIAL HYPERTENSION
    (2016) MALACHIAS, Marcus Vinicius Bolivar; SOUZA, Weimar Kunz Sebba Barroso de; PLAVNIK, Frida Liane; RODRIGUES, Cibele Isaac Saad; BRANDAO, Andrea Araujo; NEVES, Mario Fritsch Toros; BORTOLOTTO, Luiz Aparecido; FRANCO, Roberto Jorge da Silva; FIGUEIREDO, Carlos Eduardo Poli de; JARDIM, Paulo Cesar Brandao Veiga; AMODEO, Celso; BARBOSA, Eduardo Costa Duarte; KOCH, Vera; GOMES, Marco Antonio Mota; PAULA, Rogerio Baumgratz de; PAVOA, Rui Manuel dos Santos; COLOMBO, Fernanda Consolim; FERREIRA FILHO, Sebastiao; MIRANDA, Roberto Dischinger; MACHADO, Carlos Alberto; NOBRE, Fernando; NOGUEIRA, Armando da Rocha; MION JUNIOR, Decio; KAISER, Sergio; FORJAZ, Claudia Lucia de Moraes; ALMEIDA, Fernando Antonio; MARTIM, Jose Fernando Vilela; SASS, Nelson; DRAGER, Luciano Ferreira; MUXFELDT, Elizabeth; BODANESE, Luiz Carlos; FEITOSA, Audes Diogenes; MALTA, Deborah; FUCHS, Sandra; MAGALHAES, Maria Eliane; OIGMAN, Wille; MOREIRA FILHO, Osni; PIERIN, Angela Maria Geraldo; FEITOSA, Gilson Soares; BORTOLOTTO, Maria Rita de Figueiredo Lemos; MAGALHAES, Lucelia Batista Neves Cunha; SILVA, Ana Cristina Simoes e; RIBEIRO, Jose Marcio; BORELLI, Flavio Antonio de Oliveira; GUS, Miguel; PASSARELLI JUNIOR, Oswaldo; TOLEDO, Juan Yugar; SALLES, Gil Fernando; MARTINS, Luis Cuadrado; JARDIM, Thiago de Souza Veiga; GUIMARAES, Isabel Cristina Britto; ANTONELLO, Ivan Carlos; LIMA JUNIOR, Emilton; MATSUDO, Victor; SILVA, Giovanio Vieira da; COSTA, Lilian Soares da; ALESSI, Alexandre; SCALA, Luiz Cezar Nazario; COELHO, Eduardo Barbosa; SOUZA, Dilma de; LOPES, Heno Ferreira; GOWDAK, Marcia Maria Godoy; CORDEIRO JUNIOR, Antonio Carlos; TORLONI, Maria Regina; KLEIN, Marcia Regina Simas Torres; NOGUEIRA, Paulo Koch; LOTAIF, Leda Aparecida Daud; ROSITO, Guido Bernardo Aranha; MORENO JUNIOR, Heitor
  • article 4 Citação(ões) na Scopus
    Resistant Hypertension in Pregnancy: How to Manage?
    (2018) BORTOLOTTO, Maria Rita; FRANCISCO, Rossana Pulcineli Vieira; ZUGAIB, Marcelo
    The concept of resistant hypertension may be changed during pregnancy by the physiological hemodynamic changes and the particularities of therapy choices in this period. This review discusses the management of pregnant patients with preexisting resistant hypertension and also of those who develop severe hypertension in gestation and puerperium. The main cause of severe hypertension in pregnancy is preeclampsia, and differential diagnosis must be done with secondary or primary hypertension. Women with preexisting resistant hypertension may need pharmacological therapy adjustment. Several drugs can be used to treat severe hypertension, with exception of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists. The most used drugs are methyldopa, beta-blockers, and calcium channel antagonists. There is a general agreement that severe hypertension must be treated, but there are still debates over the goals of the treatment. Delivery is indicated in viable pregnancies in which blood pressure control is not achieved with three drugs in full doses. Resistant hypertension may arise in postpartum. The management of resistant hypertension in pregnancy must regard the possible etiology, the fetal well-being, and the mother's risk. Good care is mandatory to reduce maternal mortality risk.
  • article 1 Citação(ões) na Scopus
    Venous thromboembolism risk score during hospitalization in pregnancy: results of 10694 prospective evaluations in a clinical trial
    (2023) BARROS, Venina Isabel Poco Viana Leme de; IGAI, Ana Maria Kondo; BAPTISTA, Fernanda Spadotto; BORTOLOTTO, Maria Rita de Figueiredo Lemos; PERES, Stela Verzinhasse; FRANCISCO, Rossana Pulcinelli Vieira
    Objectives: Hospitalization during pregnancy and childbirth increases the risk of Venous Thromboembolism Risk (VTE). This study applied a VTE risk score to all hospitalized pregnant women to ascertain its effectiveness in pre -venting maternal death from VTE until 3 months after discharge.Methods: In this interventional study, patients were classified as low-or high-risk according to the VTE risk score (Clinics Hospital risk score). High-risk patients (score & GE; 3) were scheduled for pharmacological Thromboprophy-laxis (TPX). Interaction analysis of the main risk factors was performed using Odds Ratio (OR) and Poisson regres-sion with robust variance.Results: The data of 10694 cases (7212 patients) were analyzed; 1626 (15.2%, 1000 patients) and 9068 (84.8%, 6212 patients) cases were classified as high-risk (score & GE; 3) and low-risk (score < 3), respectively. The main risk factors (Odds Ratio, 95% Confidence Interval) for VTE were age & GE; 35 and < 40 years (1.6, 1.4-1.8), parity & GE; 3 (3.5, 3.0-4.0), age & GE; 40 years (4.8, 4.1-5.6), multiple pregnancies (2.1, 1.7-2.5), BMI & GE; 40 kg/m2 (5.1, 4.3-6.0), severe infection (4.1, 3.3-5.1), and cancer (12.3, 8.8-17.2). There were 10 cases of VTE: 7/ 1636 (0.4%) and 3/9068 (0.03%) in the high-and low-risk groups, respectively. No patient died of VTE. The inter-vention reduced the VTE risk by 87%; the number needed to treat was 3.Conclusions: This VTE risk score was effective in preventing maternal deaths from VTE, with a low indication for TPX. Maternal age, multiparity, obesity, severe infections, multiple pregnancies, and cancer were the main risk factors for VTE.